Physician profile
Scott Farley
NPI 1487274429
$3,131.87
in general payments reported to CMS, 2019-2025
22 companies · $2,093 in 2025
The $2,093 reported for 2025 was more than what 94% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $28.52 · 2024: $1,010 · 2025: $2,093.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,131.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $860.37 | 2023-2025 | |
| Janssen Biotech, INC. | $579.27 | 2024-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $251.74 | 2024-2025 | Entyvio, Eohilia |
| Genzyme Corporation | $241.86 | 2025 | |
| Madrigal Pharmaceuticals | $168.04 | 2024-2025 | Rezdiffra, Resmetirom |
| Regeneron Healthcare Solutions, INC. | $166.68 | 2024-2025 | Dupixent |
| Ardelyx, INC. | $125.93 | 2025 | Ibsrela |
| Olympus America INC. | $120.26 | 2025 | Single Use Repositionable Clip |
| Janssen Scientific Affairs, LLC | $96.92 | 2024 | Tremfya |
| Aimmune Therapeutics, INC. | $77.31 | 2025 | Zenpep, Vowst |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $74.99 | 2024-2025 | Xifaxan |
| Gilead Sciences, INC. | $60.88 | 2024-2025 | |
| Lilly USA, LLC | $58.92 | 2024-2025 | Omvoh |
| Ipsen Biopharmaceuticals, INC | $46.91 | 2025 | Iqirvo |
| Medtronic, INC. | $46.88 | 2024 | Endoflip |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $29.14 | 2024 | Rebyota |
| Boston Scientific Corporation | $27.07 | 2025 | Apollo Esg Nxt System |
| Mirum Pharmaceuticals, INC. | $24.72 | 2025 | Livmarli |
| Intercept Pharmaceuticals, INC. | $23.27 | 2025 | |
| Merck Sharp & Dohme LLC | $19.06 | 2024 | Dificid |
| Pfizer INC. | $16.58 | 2024 | |
| Phathom Pharmaceuticals, INC. | $15.07 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Farley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.